Lineage Cell Therapeutics (LCTX) Total Liabilities (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Total Liabilities of $56.8 million for Q1 2026, up 66.69% year-over-year from $34.1 million in Q1 2025, and down 17.91% quarter-over-quarter from $69.2 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Total Liabilities (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $56.8 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 66.69% year-over-year to $56.8 million; the TTM figure through Mar 2026 stood at $56.8 million (up 66.69% YoY), while the FY2025 annual figure was $69.2 million, up 91.23% from the prior year.
- Total Liabilities for Q1 2026 stood at $56.8 million, down from $69.2 million in the prior quarter.
- The five-year high for Total Liabilities was $69.2 million in Q4 2025, with the low at $31.8 million in Q3 2024.
- The 5-year median for Total Liabilities is $43.7 million (2025), against an average of $46.8 million.
- Peak annual rise in Total Liabilities reached 422.12% in 2022, while the deepest fall reached 38.16% in 2022.
- Lineage Cell Therapeutics' Total Liabilities stood at $51.7 million in 2022, then decreased by 24.61% to $39.0 million in 2023, then fell by 7.15% to $36.2 million in 2024, then surged by 91.23% to $69.2 million in 2025, then decreased by 17.91% to $56.8 million in 2026.
- Business Quant data shows LCTX's Total Liabilities at $56.8 million in Q1 2026, $69.2 million in Q4 2025, and $68.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 46.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.42 Mn |
| Mar 31, 2026 | 56.84 Mn |
| Dec 31, 2025 | 69.24 Mn |
| Sep 30, 2025 | 68.84 Mn |
| Jun 30, 2025 | 43.69 Mn |
| Mar 31, 2025 | 34.10 Mn |
| Dec 31, 2024 | 36.21 Mn |
| Sep 30, 2024 | 31.80 Mn |
| Jun 30, 2024 | 35.93 Mn |
| Mar 31, 2024 | 37.49 Mn |
| Dec 31, 2023 | 39.00 Mn |
| Sep 30, 2023 | 39.49 Mn |
| Jun 30, 2023 | 40.43 Mn |
| Mar 31, 2023 | 44.19 Mn |
| Dec 31, 2022 | 51.73 Mn |
| Sep 30, 2022 | 53.60 Mn |
| Jun 30, 2022 | 54.42 Mn |
| Mar 31, 2022 | 59.30 Mn |
| Dec 31, 2021 | 83.65 Mn |
| Sep 30, 2021 | 11.62 Mn |